Publicacións (61) Publicacións nas que participase algún/ha investigador/a

2024

  1. AB067. New drug development for the use of PARP1-E2F1 transcriptional inhibitors in the treatment of glioblastoma

    Chinese clinical oncology, Vol. 13, pp. AB067

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients

    EMBO Molecular Medicine, Vol. 16, Núm. 7, pp. 1657-1674

  4. Antiobesity effects of intestinal gluconeogenesis are mediated by the brown adipose tissue sympathetic nervous system

    Obesity, Vol. 32, Núm. 4, pp. 710-722

  5. Antioxidant micropeptins from a Microcoleus autumnalis-dominated benthic cyanobacterial mat from Western Ireland

    Phytochemistry, Vol. 223

  6. Application of a multi-toxin detect method to analyze mycotoxins occurrence in plant-based beverages

    Food Chemistry, Vol. 434

  7. Association between endocrine and neuropsychological endophenotypes and gambling disorder severity

    Addictive Behaviors, Vol. 153

  8. Bilateral Uveal Melanoma: An Insight into Genetic Predisposition in Four New Unrelated Patients and Review of Published Cases

    Journal of Clinical Medicine, Vol. 13, Núm. 11

  9. Bioavailability profiling shows differences in OA, DTX1 and DTX2 toxins that justify their toxicity

    Chemosphere, Vol. 366

  10. Biodistribution and pharmacokinetics of [89Zr]-anti-VEGF mAbs using PET in glioblastoma rat models

    International Journal of Pharmaceutics, Vol. 652

  11. Ceramides in the central control of metabolism

    Trends in Endocrinology and Metabolism

  12. Cluster analysis in gambling disorder based on sociodemographic, neuropsychological, and neuroendocrine features regulating energy homeostasis

    Comprehensive Psychiatry, Vol. 128

  13. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  14. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  15. Correction to: Seeing through the fog: a neuroendocrine explanation for post-COVID cognitive deficits (Nature Reviews Endocrinology, (2024), 20, 4, (189-190), 10.1038/s41574-024-00955-3)

    Nature Reviews Endocrinology

  16. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  17. Cortical actions of thyroid hormone: An exploration and metabolism crossroad

    Cell metabolism, Vol. 36, Núm. 10, pp. 2170-2172

  18. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

    DIABETES THERAPY, Vol. 15, Núm. 5, pp. 1069-1084

  19. Enniatins A1 and B1 Modulate Calcium Flux through Alternative Pathways beyond Mitochondria

    Journal of Agricultural and Food Chemistry, Vol. 72, Núm. 26, pp. 14975-14983

  20. Estrogen receptor-α signaling in tanycytes lies at the crossroads of fertility and metabolism

    Metabolism: Clinical and Experimental, Vol. 158